Latest Durect Corp (DRRX) Headlines
Harwood Feffer LLP Announces Investigation of DURECT Corporation
PR Newswire - Fri Mar 07, 8:00PM CST
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against DURECT Corporation ("DURECT" or the "Company") (NASDAQ: DRRX) and its board of directors concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws.
Robbins Arroyo LLP Is Investigating the Officers and Directors of DURECT Corporation on Behalf of Shareholders
PR Newswire - Thu Mar 06, 6:30PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of the pharmaceutical company, DURECT Corporation (NasdaqGM: DRRX), breached their fiduciary duties to shareholders.
DURECT Corporation Announces Fourth Quarter 2013 Financial Results and Update of Programs
PR Newswire - Thu Feb 27, 3:05PM CST
DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2013. Total revenues were $4.3 million for the three months ended December 31, 2013 as compared to $3.3 million for the three months ended December 31, 2012. Net loss was $5.1 million for the three months ended December 31, 2013 as compared to a net loss of $5.5 million for the same period in 2012.
Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018
M2 - Mon Feb 24, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdvkjn/pain_management) has announced the addition of the "Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018" report to their offering. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics. The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 - 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations. Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter's five force analysis for the pain management therapeutics market. The competitive landscape section includes market share analysis of all the leading players in the branded pharmaceuticals market for pain management, in terms of percentage share in the year 2011. Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Global Pain Management Therapeutics Market, by Therapeutic Class 5 Global Pain Management Therapeutics Market, by Indication 6 Global Pain Management Therapeutics Market, by Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - Abbott Laboratories - Allergan - Covidien - Durect Corporation - Eli Lilly and Company - Endo Health Solutions - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Merck & Co - Mundipharma International - Novartis International - NuPathe - Pain Therapeutics - Pfizer - Purdue Pharma - QRx Pharma - Sanofi - Teva Pharmaceutical Industries - UCB (Union Chemnique Belge) For more information visit http://www.researchandmarkets.com/research/td...management
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of DURECT Corporation
PR Newswire - Thu Feb 20, 7:45AM CST
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of DURECT Corporation ("DURECT" or the "Company") (NasdaqGM -DRRX). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
DURECT CorporationCorporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:55PM CST
The following issues have been halted by IIROC:
DURECT Corporation Invites You to Join its Fourth Quarter 2013 Earnings Conference Call and Upcoming Investor Conference
PR Newswire - Tue Feb 18, 7:30AM CST
In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 27, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
America's Top 5 Health Threats in 2014
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 16, 11:31AM CST
According to the World Health Organization, as of 2011 there were 12,420 different diseases, disorders, and ailments that can afflict the human body. This cornucopia of diseases and disorders ranges from more of the nuisance variety to...
This Week in Biotech: Three Strikes and You're Out!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 15, 1:10PM CST
With the SPDR S&P Biotech Index up 64% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DURECT Corporation - DRRX
PR Newswire - Fri Feb 14, 1:56PM CST
Pomerantz LLP is investigating claims on behalf of investors of DURECT Corporation ("DURECT" or the "Company")(NasdaqGS: DRRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
Nasdaq stocks posting largest volume increases
AP - Thu Feb 13, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why DURECT Corporation Shares Were Walloped
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 13, 12:34PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DURECT , a specialty pharmaceutical...
DURECT Receives Complete Response Letter from FDA for POSIDUR(TM) (SABER®-Bupivacaine)
PR Newswire - Wed Feb 12, 3:43PM CST
DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for POSIDUR(TM) (SABER®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia. Based on its review, the FDA has determined that they cannot approve the NDA in its present form, stating the NDA does not contain sufficient information to demonstrate that POSIDUR is safe when used in the manner described in the proposed label, and the FDA has indicated that additional clinical safety studies need to be conducted. DURECT is evaluating the issues described in the Complete Response Letter and plans to have further discussions with the FDA around them.
This Is America's Fastest-Growing Drug Problem
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 09, 1:15PM CST
There are few wars that the United States can conceivably say it's not won, but the war on illicit drugs and general drug abuse continues to be one such instance where there's no clear victory in sight. According to a National Drug Threat Survey ...
Hot Stock: Durect, Shares Gain 6.3% (DRRX)
Comtex SmarTrend(R) - Thu Feb 06, 12:46PM CST
Durect (NASDAQ
RRX) is one of today's best performing low-priced stocks, up 6.3% to $2.04 on 1.0x average daily volume. Thus far today, Durect has traded 1.2 million shares, vs. average volume of 1.2 million shares per day. The stock has outperformed the Dow (6.3% to the Dow's 0.9%) and outperformed the S&P 500 (6.3% to the S&P's 0.9%) during today's trading.
Impax and DURECT enter into USD63m agreement to develop and commercialise DURECT's ELADUR
M2 - Wed Jan 08, 4:56AM CST
Impax Laboratories Inc (Nasdaq:IPXL), a technology based specialty pharmaceutical company, and DURECT Corporation (Nasdaq RRX), a specialty pharmaceutical company, announced on Tuesday the signing of an agreement granting Impax the exclusive worldwide rights to develop and commercialise ELADUR, DURECT's investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia (PHN).
Stock to Watch: Durect Up 7.3% (DRRX)
Comtex SmarTrend(R) - Tue Jan 07, 10:42AM CST
Durect (NASDAQ RRX) is one of today's best performing low-priced stocks, up 7.3% to $1.91 on 2.1x average daily volume. Durect has traded 1.3 million shares thus far today, vs. average volume of 617,000 shares per day. The stock has outperformed the Dow (7.3% to the Dow's 0.7%) and outperformed the S&P 500 (7.3% to the S&P's 0.6%) during today's trading.
Impax Labs will develop Durect pain patch
AP - Tue Jan 07, 10:25AM CST
NEW YORK (AP) — Impax Laboratories said Tuesday that it will develop and market Durect's Eladur patch, which is designed to treat pain associated with the viral infection shingles.
Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT's ELADUR(R) Pain Patch
Business Wire - Tue Jan 07, 7:00AM CST
Impax Laboratories, Inc.(NASDAQ:IPXL) and DURECT Corporation (Nasdaq RRX) announced today that they have entered into an agreement granting Impax the exclusive worldwide rights to develop and commercialize ELADUR(R), DURECT's investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia (PHN).
Harwood Feffer LLP Announces Investigation of DURECT Corporation
PR Newswire - Fri Mar 07, 8:00PM CST
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against DURECT Corporation ("DURECT" or the "Company") (NASDAQ: DRRX) and its board of directors concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws.
Robbins Arroyo LLP Is Investigating the Officers and Directors of DURECT Corporation on Behalf of Shareholders
PR Newswire - Thu Mar 06, 6:30PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of the pharmaceutical company, DURECT Corporation (NasdaqGM: DRRX), breached their fiduciary duties to shareholders.
DURECT Corporation Announces Fourth Quarter 2013 Financial Results and Update of Programs
PR Newswire - Thu Feb 27, 3:05PM CST
DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2013. Total revenues were $4.3 million for the three months ended December 31, 2013 as compared to $3.3 million for the three months ended December 31, 2012. Net loss was $5.1 million for the three months ended December 31, 2013 as compared to a net loss of $5.5 million for the same period in 2012.
Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018
M2 - Mon Feb 24, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdvkjn/pain_management) has announced the addition of the "Concise Analysis of the International Pain Management Therapeutics Market - Forecasts to 2018" report to their offering. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics. The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 - 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations. Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter's five force analysis for the pain management therapeutics market. The competitive landscape section includes market share analysis of all the leading players in the branded pharmaceuticals market for pain management, in terms of percentage share in the year 2011. Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Global Pain Management Therapeutics Market, by Therapeutic Class 5 Global Pain Management Therapeutics Market, by Indication 6 Global Pain Management Therapeutics Market, by Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - Abbott Laboratories - Allergan - Covidien - Durect Corporation - Eli Lilly and Company - Endo Health Solutions - Forest Laboratories - GlaxoSmithKline - Hospira - Johnson & Johnson - Merck & Co - Mundipharma International - Novartis International - NuPathe - Pain Therapeutics - Pfizer - Purdue Pharma - QRx Pharma - Sanofi - Teva Pharmaceutical Industries - UCB (Union Chemnique Belge) For more information visit http://www.researchandmarkets.com/research/td...management
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of DURECT Corporation
PR Newswire - Thu Feb 20, 7:45AM CST
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of DURECT Corporation ("DURECT" or the "Company") (NasdaqGM -DRRX). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
DURECT CorporationCorporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:55PM CST
The following issues have been halted by IIROC:
DURECT Corporation Invites You to Join its Fourth Quarter 2013 Earnings Conference Call and Upcoming Investor Conference
PR Newswire - Tue Feb 18, 7:30AM CST
In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 27, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
America's Top 5 Health Threats in 2014
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 16, 11:31AM CST
According to the World Health Organization, as of 2011 there were 12,420 different diseases, disorders, and ailments that can afflict the human body. This cornucopia of diseases and disorders ranges from more of the nuisance variety to...
This Week in Biotech: Three Strikes and You're Out!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 15, 1:10PM CST
With the SPDR S&P Biotech Index up 64% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DURECT Corporation - DRRX
PR Newswire - Fri Feb 14, 1:56PM CST
Pomerantz LLP is investigating claims on behalf of investors of DURECT Corporation ("DURECT" or the "Company")(NasdaqGS: DRRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
Nasdaq stocks posting largest volume increases
AP - Thu Feb 13, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why DURECT Corporation Shares Were Walloped
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 13, 12:34PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DURECT , a specialty pharmaceutical...
DURECT Receives Complete Response Letter from FDA for POSIDUR(TM) (SABER®-Bupivacaine)
PR Newswire - Wed Feb 12, 3:43PM CST
DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for POSIDUR(TM) (SABER®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia. Based on its review, the FDA has determined that they cannot approve the NDA in its present form, stating the NDA does not contain sufficient information to demonstrate that POSIDUR is safe when used in the manner described in the proposed label, and the FDA has indicated that additional clinical safety studies need to be conducted. DURECT is evaluating the issues described in the Complete Response Letter and plans to have further discussions with the FDA around them.
This Is America's Fastest-Growing Drug Problem
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 09, 1:15PM CST
There are few wars that the United States can conceivably say it's not won, but the war on illicit drugs and general drug abuse continues to be one such instance where there's no clear victory in sight. According to a National Drug Threat Survey ...
Hot Stock: Durect, Shares Gain 6.3% (DRRX)
Comtex SmarTrend(R) - Thu Feb 06, 12:46PM CST
Durect (NASDAQ
RRX) is one of today's best performing low-priced stocks, up 6.3% to $2.04 on 1.0x average daily volume. Thus far today, Durect has traded 1.2 million shares, vs. average volume of 1.2 million shares per day. The stock has outperformed the Dow (6.3% to the Dow's 0.9%) and outperformed the S&P 500 (6.3% to the S&P's 0.9%) during today's trading. Impax and DURECT enter into USD63m agreement to develop and commercialise DURECT's ELADUR
M2 - Wed Jan 08, 4:56AM CST
Impax Laboratories Inc (Nasdaq:IPXL), a technology based specialty pharmaceutical company, and DURECT Corporation (Nasdaq
RRX), a specialty pharmaceutical company, announced on Tuesday the signing of an agreement granting Impax the exclusive worldwide rights to develop and commercialise ELADUR, DURECT's investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia (PHN). Stock to Watch: Durect Up 7.3% (DRRX)
Comtex SmarTrend(R) - Tue Jan 07, 10:42AM CST
Durect (NASDAQ
RRX) is one of today's best performing low-priced stocks, up 7.3% to $1.91 on 2.1x average daily volume. Durect has traded 1.3 million shares thus far today, vs. average volume of 617,000 shares per day. The stock has outperformed the Dow (7.3% to the Dow's 0.7%) and outperformed the S&P 500 (7.3% to the S&P's 0.6%) during today's trading. Impax Labs will develop Durect pain patch
AP - Tue Jan 07, 10:25AM CST
NEW YORK (AP) — Impax Laboratories said Tuesday that it will develop and market Durect's Eladur patch, which is designed to treat pain associated with the viral infection shingles.
Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT's ELADUR(R) Pain Patch
Business Wire - Tue Jan 07, 7:00AM CST
Impax Laboratories, Inc.(NASDAQ:IPXL) and DURECT Corporation (Nasdaq
RRX) announced today that they have entered into an agreement granting Impax the exclusive worldwide rights to develop and commercialize ELADUR(R), DURECT's investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia (PHN). 
